Day: January 30, 2023

Posted on

Fortinet Expands its Services and Training Offerings to Further Support SOC Teams in Preventing and Defending Against Cyber Threats

Multi-Faceted Approach Accelerates Fortinet’s Global Commitment to Eliminate the Cybersecurity Skills Gap

SUNNYVALE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) —

John Maddison, EVP of Products and CMO at Fortinet
“Fortinet builds ML-driven automation into all of its SOC offerings to support short-staffed teams affected by the cybersecurity skills shortage. But technology alone won’t solve this issue, which is why we are dedicated to also delivering human-based SOC augmentation services to provide immediate support, while investing in an industry-leading training institute to close the cybersecurity skills gap. This combination of technology, services, and training enables SOC professionals to better protect their organizations from detection to incident recovery.”

News Summary
Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated, and automated cybersecurity solutions, today announced new security operations center (SOC) augmentation services designed to help strengthen an organization’s cyber resiliency and support short-staffed teams strained by the talent shortage. In addition, as part of Fortinet’s leadership efforts to help close the cyber skills gap, the Fortinet Training Institute has added initiatives across its programs to further increase access to its industry-recognized training and certifications.

Cybersecurity Skills Shortage Prompts a New Approach
The prevailing talent shortage remains one of the top challenges facing SOC teams globally. Fortinet’s 2022 Cybersecurity Skills Gap report found that 50% of global leaders cite security operations as one of the most challenging roles to fill, and 42% are still in need of security operations analysts. Additionally, the same Fortinet survey found that worldwide, 80% of organizations suffered one or more breaches due to a lack of cybersecurity skills and awareness.

A lack of resources and personnel, combined with the sheer volume of security alerts SOC teams receive per day, often results in missed detections and slower responses that increase exposure to cyber risk. SOC teams require an immediate solution to mitigate these challenges through investment in automated and integrated SOC and cybersecurity technologies and experienced professionals to better protect against threats.

New and Enhanced SOC Augmentation Services Provide Immediate Support for Short-Staffed Security Operations Teams

Committed to helping organizations overcome these obstacles, Fortinet’s new and enhanced services help SOC teams reduce their organizations’ cyber risk while freeing up their time to focus on higher-priority projects. These updates include:

  • SOC-as-a-Service (SOCaaS): Fortinet has expanded its SOCaaS offering, which blends FortiGuard cybersecurity experts with Fortinet advanced SOC technology by adding more artificial intelligence (AI) and machine learning (ML) capabilities to additional use cases. These updates enhance the offering’s ability to aggregate security alerts in one single cloud-based dashboard for customers to view actionable intelligence and accelerate resolution, and further enables security operations teams to offload monitoring and detection to Fortinet security experts. With this approach, Fortinet speeds up alert triage, rapidly escalates security incidents, and reduces false-positive alerts for customers.
  • Outbreak Detection Service: A new outbreak detection service is available to customers that alerts subscribers through email as well as automatically within key product user interfaces to major breaking cybersecurity events that have the potential for widespread ramifications. These alerts include critical information about security incidents, such as an attack’s timeline of events and what specific technology has been affected. In addition, the alerts also provide organizations with custom threat hunting to run against logs and identify the potential impact of an attack, as well as recommendations to improve their security posture for better protection in the future.
  • Incident Response and Readiness (IR&R) Services: Fortinet recently added cybersecurity readiness services as part of its Incident Response offering and shifted the purchasing model to prioritize prevention. By providing a suite of proactive prevention-oriented services, such as risk assessments, playbook development, and tabletop exercises as part of the Incident Response and Readiness Services retainer, organizations can strengthen their cyber preparedness, SOC effectiveness, and reduce cyber risk, while still having access to a team of FortiGuard experts to help with rapid containment and remediation in the event of a cyberattack. In response to an accelerated demand for these services around the globe, Fortinet is also expanding its headcount dedicated to IR&R and SOC automation capabilities to allow more enterprises to have access to the offering.

Expanding Cyber Skills Through the Fortinet Training Institute
While the new and enhanced SOC augmentation services provide immediate relief to strained teams, a long-term investment in continued learning and advancing cyber skills is just as critical to keep up with the ever-changing threat landscape. As part of Fortinet’s longstanding commitment to eliminate the skills gap, the Fortinet Training Institute offers award-winning, multi-level training and certifications to security professionals seeking to advance and upskill their knowledge in key cybersecurity areas. These programs also help untap new talent pools to help build the cyber workforce of the future, with a focus on providing training opportunities for women, veterans, students, and underserved populations. Some recent updates across programs include:

  • Increasing Access to Advanced Technical Training: Fortinet has made the practical exam for NSE level 8 more accessible for IT and security professionals everywhere. Both the written and practical portions of the exam are now available in an online, proctored format, making the highest and most elite level of the Network Security Expert (NSE) Certification program more accessible to security professionals around the world.
  • Supporting the Advancement of Women Professionals in Cybersecurity: The first women cohort of the Fortinet and Women in Cybersecurity (WiCyS) bootcamp completed the program, which offered 100 WiCyS members access to Fortinet’s NSE level 4 training and labs for free, technical mentors, exam vouchers, and more. Fortinet has also awarded five of the program participants with scholarships to attend the annual WiCyS Conference March 16–18, where they will have access to cyber leaders and employers.
  • Developing Cybersecurity Skills in Youth: To further develop the cyber workforce of the future, Fortinet is sponsoring various cybersecurity-based competitions for students in varying academic levels, ranging from middle school to college. This includes being a platinum sponsor of MITRE Engenuity’s Embedded Capture the Flag (eCTF) 12-week competition and a category sponsor for the Carnegie Mellon Capture the Flag competition.

Through these initiatives, Fortinet is progressing toward the company’s pledge to train 1 million people in cybersecurity by 2026. Additionally, Fortinet’s new and enhanced SOC augmentation services build on its expansive services portfolio backed by FortiGuard Labs. With today’s announcement, Fortinet remains committed to alleviating the challenges associated with the cybersecurity talent shortage by helping organizations better manage cyber risks with ML-driven automation, services, and increased access to training.

Additional Resources

About Fortinet
Fortinet (NASDAQ: FTNT) makes possible a digital world that we can always trust through its mission to protect people, devices, and data everywhere. This is why the world’s largest enterprises, service providers, and government organizations choose Fortinet to securely accelerate their digital journey. The Fortinet Security Fabric platform delivers broad, integrated, and automated protections across the entire digital attack surface, securing critical devices, data, applications, and connections from the data center to the cloud to the home office. Ranking #1 in the most security appliances shipped worldwide, more than 615,000 customers trust Fortinet to protect their businesses. And the Fortinet NSE Training Institute, an initiative of Fortinet’s Training Advancement Agenda (TAA), provides one of the largest and broadest training programs in the industry to make cyber training and new career opportunities available to everyone. Learn more at https://www.fortinet.com, the Fortinet Blog, and FortiGuard Labs.

FTNT-O

Copyright © 2023 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiMail, FortiSandbox, FortiADC, FortiAI, FortiAIOps, FortiAntenna, FortiAP, FortiAPCam, FortiAuthenticator, FortiCache, FortiCall, FortiCam, FortiCamera, FortiCarrier, FortiCASB, FortiCentral, FortiConnect, FortiController, FortiConverter, FortiCWP, FortiDB, FortiDDoS, FortiDeceptor, FortiDeploy, FortiDevSec, FortiEdge, FortiEDR, FortiExplorer, FortiExtender, FortiFirewall, FortiFone, FortiGSLB, FortiHypervisor, FortiInsight, FortiIsolator, FortiLAN, FortiLink, FortiMoM, FortiMonitor, FortiNAC, FortiNDR, FortiPenTest, FortiPhish, FortiPlanner, FortiPolicy, FortiPortal, FortiPresence, FortiProxy, FortiRecon, FortiRecorder, FortiSASE, FortiSDNConnector, FortiSIEM, FortiSMS, FortiSOAR, FortiSwitch, FortiTester, FortiToken, FortiTrust, FortiVoice, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLM and FortiXDR. Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments.

Media Contact: Investor Contact: Analyst Contact:
Camille Burdge Peter Salkowski Brian Greenberg
Fortinet, Inc. Fortinet, Inc. Fortinet, Inc.
408-235-7700 408-331-4595 408-235-7700
pr@fortinet.com psalkowski@fortinet.com analystrelations@fortinet.com

GlobeNewswire Distribution ID 8738473

Posted on

Cozycozy is the Only Accommodation Search Engine That Now Includes Airbnb, Giving Travelers the Largest Selection of Vacation Rentals Possible

One search, so many possibilities – cozycozy helps users find their perfect holiday accommodation from over 100+ booking platforms, including Airbnb.

cozycozy Amalfi coast

cozycozy Amalfi coast

NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) — Cozycozy knows that finding the perfect place to stay can be hard. With the rise of so many vacation rental and hotel platforms comes more and more options, overwhelming travelers.

“The days of having multiple tabs open to find the best deal are over,” says Romain Claudel, co-founder of cozycozy. “We created cozycozy.com so travelers can see all their options in one place, without all the hassle.”

There are more and more vacation rentals and hotel rooms listed on several platforms, often with rates that vary. By using cozycozy, users conveniently get the lowest price possible. Their website allows users to see a comprehensive list of available options all at once, so that they get the best rates.

They are the only platform in the world to include Airbnb in its search engines, letting users compare Airbnb prices with competitor sites like VRBO, Booking.com and Expedia. With cozycozy, what you see is what you get – prices displayed on their platform include all fees, so there are no surprises at the time of booking.

Their intuitive search engine helps travelers find the best offer, so they find the accommodation that exactly fits their needs, while saving time and money.
About Cozycozy: 

Cozycozy is the world’s only search engine that browses over hundreds of booking platforms, including Airbnb, so travelers can find their perfect stay in just one click. Launched in 2019, the platform is now operating in 39 countries worldwide.

Users can customize their experience by applying helpful filters like family stays, pet-friendly, free cancellation, quality/price, and more, to help them narrow down their search and find their ideal location. They can choose classic stays like hotels, apartments, cabins, and home options, or more remarkable stays like boats, glamping tents, and treehouses.

Cozycozy puts users first. Its technology makes it easy to use and quickly shows over 20 million listings available. The platform offers the best pricing possible because it is fully transparent and free of commercial bias—no hidden fees.

Contact Information:
Mayra Lopez-Rocha
PR manager
press@cozycozy.com
+33768723121

Related Images

Image 1: cozycozy Amalfi coast

Amalfi coast

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8738819

Posted on

Junshi Biosciences Announces Approval for Marketing of VV116 in China

SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (“COVID-19”).

VV116 is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase (“RdRp”) of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect. Preclinical studies have shown that VV116 exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity.

VV116 was jointly developed by the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences, Wuhan Institute of Virology at the Chinese Academy of Sciences, Xinjiang Technical Institute of Physics and Chemistry at the Chinese Academy of Sciences, Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences) / China-Uzbekistan Medicine Technical Park (“the Belt and Road” Joint Laboratory of the Ministry of Science and Technology), Lingang Laboratory, Vigonvita Life Sciences Co., Ltd. (“Vigonvita”) and Junshi Biosciences

This approval is mainly based on a multi-center, double-blind, randomized, placebo-controlled phase III clinical study (NCT05582629) evaluating the efficacy and safety of VV116 among mild to moderate COVID-19 patients with or without high risk of progression to severe COVID-19. The study was led by academician Lanjuan LI, Director of the State Key Laboratory for Diagnosis & Treatment of Infectious Diseases (Zhejiang University) as primary investigator. The primary endpoint of the study was the time to sustained clinical symptoms resolution, while the secondary endpoints included the time to sustained clinical symptoms alleviation, percentage of participants with disease progression to severe or critical COVID-19 or death by any cause by day 28, changes in SARS-CoV-2 nucleic acid and viral load, safety, and etc.

The study results showed that as of the data cut-off date of the interim analysis, among 1,277 randomized and treated subjects, the primary endpoint, or the time from first administration to sustained clinical symptoms resolution (The score of 11 COVID-19 related clinical symptom =0 and lasted for 2 days) of the VV116 group was significantly shortened when compared with that of the placebo group, and the median time difference was 2 days; similarly, the time to sustained clinical symptoms alleviation was also significantly shortened, and the change of viral load from baseline and other virological indicators were better than those of the placebo group.

About Deuremidevir Hydrobromide Tablets (VV116/JT001)
VV116 is an oral nucleoside analog drug that can inhibit the replication of SARS-CoV-2. During preclinical pharmacodynamic studies, VV116 exerted an antiviral effect on the original strain of the novel corinavirus and its known variants in vitro; in the mice model, a low dose of VV116 reduced the virus titers below the detection limit, significantly lowered the chances of lung injury and displayed a strong antiviral effect. Preclinical pharmacokinetics and other research results also show that VV116 has high oral bioavailability. Following oral administration and absorption, VV116 is rapidly metabolized into parent nucleoside and widely distributed throughout the body.

VV116 was jointly developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; the Wuhan Institute of Virology, Chinese Academy of Sciences; Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences; Central Asian Center of Drug Discovery and Development Chinese Academy of Sciences / China-Uzbekistan Medicine Technical Park (the Joint Laboratory of the Ministry of Science and Technology under the “The Belt and Road Initiative”); Lingang Laboratory; Vigonvita Life Sciences Co., Ltd. (“Vigonvita”); and Junshi Biosciences. Junshi Biosciences and Vigonvita are responsible for the clinical development and industrialization of VV116 worldwide. The areas of cooperation is global aside from five Central Asian countries, Russia, North Africa and the Middle East.

Junshi Biosciences and Vigonvita have completed three Phase I studies with healthy Chinese subjects, and one Phase III study in the patients with mild-to moderate COVID-19 at high risk to progression to severe COVID-19 in China (NCT05341609). Research results have been published in Acta Pharmacologica Sinica, and NEJM respectively. Aside from that, one Phase III study in the patients with or without high risk of progression to severe COVID-19 has completed its pre-specified interim analysis, and met the pre-defined primary efficacy endpoint.

In December 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19. In January 2023, VV116 was approved for marketing in China for the treatment of adult patients with mild to moderate COVID-19.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8738872

Posted on

Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections

— ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations–

— Survey was conducted through COPD360Net®, an innovative COPD Foundation program that identifies unmet patient needs and integrates the patient voice into therapy development–

MIAMI and MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) — A survey conducted collaboratively by the COPD Foundation, a not-for-profit organization established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, and ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylaxis of respiratory viral infections for populations at risk of complications, found patients were overwhelmingly positive about the prospect of taking an antiviral nasal spray throughout the winter season or when at risk for exposure to a respiratory virus to prevent COPD flare-ups. The survey results were published in the January issue of the Journal of Patient Experience.

The survey was conducted through the COPD Foundation’s COPD360Net® initiative, which facilitates connections between patients with chronic lung diseases, researchers, and other stakeholders to identify unmet patient needs and accelerate new therapy options. The vast majority (>80%) of the 376 patients surveyed expressed interest in a potential new seasonal anti-viral nasal spray, taken either twice weekly during the winter months or for two weeks after exposure to someone with a respiratory illness. Over half (56-58%) of patients with frequent COPD exacerbations were very interested.

Nearly all patients surveyed say they are vaccinated (>92%) for the flu, pneumonia, and COVID-19 and that they have previously taken antiviral medication during cold and flu season. Even so, more than a third (35%) report that viral illnesses have sometimes resulted in hospitalization and nearly half (45%) have needed antibiotics or steroids to treat complications of a viral illness. About 1 in 8 (12%) say they have been treated in an intensive care unit due to complications of a respiratory illness.

“These survey results validate the need for seasonal prophylaxis against respiratory viral infections and the value of INNA-051 for patients at high risk of complications from the flu, colds, COVID-19 and other common respiratory illnesses” said Christophe Demaison, Ph.D., co-founder and CEO of ENA Respiratory.

“Patient insights are critical to successful therapy development, but too often the patient’s voice isn’t heard. These survey results provide additional evidence that we need more tools in the toolbox to protect people with chronic lung diseases during cold and flu season and prevent flare-ups and complications,” said Ruth Tal-Singer, Ph.D., president of 360Net, COPD Foundation.

ENA Respiratory and the COPD Foundation launched a partnership in 2022 to develop INNA-051 for people with chronic lung diseases. The partnership added INNA-051 to the COPD Foundation’s COPD360Net® pipeline and is utilizing its global network of accredited centers, scientific expertise, and patient investigators to optimize and accelerate the clinical development program.

Recently, ENA Respiratory was awarded a $4.38 million grant from the U.S. Department of Defence to support the development of INNA-051. In a Phase 1 study, INNA-051 was found to be well-tolerated, and the company expects to share Phase 2a results soon.

Notes to Editors

If you would like to arrange an interview, please contact:

About ENA Respiratory and INNA-051

ENA Respiratory is aiming to transform the prevention of respiratory viral infections in populations at-risk of complications. The company is based in Melbourne and Sydney, Australia and it has secured a Series A investment from Brandon Capital Partners’ managed funds, the Minderoo Foundation, and Uniseed.

INNA-051 is a potent innate immune TLR2/6 agonist. It is being developed for intranasal delivery to target the primary entry site of viral respiratory infections as most respiratory viruses, including SARS-CoV-2 and influenza, initially infect and replicate in nasal mucosa epithelial cells. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. INNA-051 and close analogues have been shown in preclinical studies to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

Key features of INNA-051 intranasal administration include limited minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation which is known to be associated with fever in humans, durable immune response supporting weekly administration, and compatibility with vaccine and intranasal corticosteroids.

For more information, please visit https://enarespiratory.com

About the COPD Foundation

The COPD Foundation is a not-for-profit organization established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease through initiatives that expand services and speed innovations to make treatment more effective and affordable. The Foundation does this through scientific research, education, advocacy, and awareness to prevent disease, slow progression, and find a cure. For more information, visit https://www.copdfoundation.org/, or follow us on Twitter and LinkedIn.

GlobeNewswire Distribution ID 8738190

Posted on

Photonis Brings Market-Leading Single Photon Detection and Imaging Solutions to SPIE Photonics West 2023

Photonis Logo

SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) — Photonis has announced their participation at the SPIE Photonics West Conference, taking place Jan. 31-Feb. 2, 2023, at the Moscone Center, San Francisco, California, USA.

The Scientific Detectors team will present their advanced Single Photon Detection and Imaging solutions targeting Quantum Optics, High-Energy Physics and Plasma Research markets, offering industry-leading detection efficiency, ultra-low noise operation and high-temporal resolution in a cost-effective robust package.

Single photon detection and imaging solutions include: Ultra-Fast MCP-PMTs for Single Photon Counting applications, The Cricket2 plug & play camera attachment for single photon imaging functionality, and the game-changing Mantis3, a high-rate, event-driven, time-stamping camera for Single Photon Imaging applications.

“We are thrilled to have the opportunity to present at this year’s SPIE Photonics West conference,” said Ulrich Laupper, President and GM of Photonis Scientific. “We are proud to demonstrate the unprecedented capabilities of our single photon counting and imaging solutions which will provide Researchers and Scientists, for the first time, the tools they need to accurately detect every photon.”

Photonis has a long history of developing innovative and award-winning photonics products, offering a wide range of fast counting and imaging detectors with high spatial resolution and ultra-fast gating capabilities.

Visit Photonis at booth #1437 during SPIE Photonics West to experience the unparalleled sensitivity and resolution of Photonis’ Single Photon detection and imaging devices. Attendees are encouraged to meet and speak with the company’s diverse team of technical experts to learn more about how Photonis’ Single Photon detections and imaging solutions can benefit almost any application or research setting, allowing you to capture every photon.

For more information on Photonis’ Single Photon Detection, Counting and Imaging solutions, please visit: https://www.photonis.com/.

About Photonis

Photonis is a market-leading provider of electro-optic solutions used in the detection and amplification of ions, electrons, and photons. We are focused on mission-critical components aimed at highly demanding customers. We innovate and engineer quality components for integration into a variety of applications, such as night vision optics, digital cameras, mass spectrometry, physics research, space exploration, and many others.

We design and manufacture in our facilities across the globe and work with our customers to continually improve and innovate our products. We are the most widely deployed night vision tube globally, lead the mass spectrometer detector market, and have products installed in most space telescopes and high-energy physics experiments in laboratories around the world.

Contact Information:
Rob Fisher
Head of Sales & Marketing – optics.org
rob.fisher@optics.org
+44 117 905 5330

Robert Gordon
Account Executive, Photonics Media
robert.gordon@photonics.com
9498781314

Philip Melnik
North American Sales Manager, AZO Network
philmelnik@azonetwork.com
5187655632

Related Images

Image 1: Photonis Logo

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8738408

Posted on

FourKites and cargonerds Partner to Bring Enhanced Cost & Time Savings to Global Freight Forwarders and Shippers

FourKites and cargonerds Partner

Companies Bring Enhanced Cost & Time Savings to Global Freight Forwarders and Shippers

CHICAGO, Jan. 30, 2023 (GLOBE NEWSWIRE) — Leading real-time supply chain visibility company FourKites today announced a partnership with cargonerds to enhance the digital freight platform with its market-leading supply chain visibility data.

Armed with FourKites’ data and machine learning-driven estimated times of arrival, cargonerds can now ensure that its freight forwarders and their customers can track products across the end-to-end supply chain and know exactly when they will arrive at their destination. The integrated solution will track global shipments in real time across road, rail, ocean, air, parcel and last mile across the globe.

“FourKites has the largest global network of supply chain data and powerful machine learning on the planet,” says Conrad Franchi, founder of cargonerds. “Their end-to-end solution enables us to give our customers the most accurate ETAs (estimated time of arrivals) and greater network collaboration. Having the right data at the right time to identify precisely what can be done is the only path to proactively mitigating issues while reducing costs and fees.”

FourKites and cargonerds Partner

Marc Boileau, FourKites’ Senior Vice President Sales, Network & Operations EMEA

Hamburg, Germany-based cargonerds — a spin-off of Rohlig Logistics — is a software development company that serves small and medium-sized freight forwarders. In 2022, cargonerds moved 250.000 ocean shipments, 250.000 air shipments and 150.000 road shipments. Their mission is to unlock the value of digital supply chains and thus make it accessible for smaller freight forwarders.

“Many times, small and medium sized freight forwarders don’t have access to services like supply chain visibility because they lack software development resources and implementation skills,” Conrad continued.

cargonerd’s freight forwarders can now send data about each shipment in transit directly and securely to their supply chain stakeholders. In doing so, their customers can streamline communication, more easily collaborate with partners and increase on-time deliveries.

“Our technology is perfectly suited for logistics service providers, and we’re thrilled to partner with cargonerds to expand our footprint globally,” says Marc Boileau, FourKites’ Senior Vice President Sales, Network & Operations EMEA. “FourKites’ digitized solution will eliminate manual tracking from cargonerds’ network of freight forwarders and customers, saving significant time and resources and enabling them to shift focus to higher-value tasks.”

FourKites and cargonerds Partner

Conrad Franchi, founder of cargonerds

cargonerds will be showcasing its solution with FourKites and the value it brings to both carriers and shippers in a live webinar taking place on Wednesday, February 15, 2023. Register here.

About FourKites
Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

About cargonerds
cargonerds — the digital angel for medium-sized global freight forwarders — offers plug-and-play software solutions for quoting, booking, tracking, and reporting. International airfreight and sea freight forwarders can offer a first digital customer experience within 48 hours through the rapid implementation approach. The company partners with leading logistics software and data providers, such as FourKites, Magaya, and WebCargo to unlock digital innovations for 3PL companies. The software products can integrate with any existing TMS or ERP system setup. The products can also create a digital data network between agencies. More than 500,000 global shipments are being managed annually. The software development company is based in Hamburg, Germany, and offers its cloud products worldwide. To learn more, visit https://cargonerds.com/.

Media Contacts
Marianna Vyridi
Big Valley Marketing for FourKites
(650) 468-3263
mvyridi@bigvalley.co

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/98064a20-b250-4ae9-8401-77a77128affc

https://www.globenewswire.com/NewsRoom/AttachmentNg/80bce1c6-ed30-47b0-9af1-47d7e8622bf3

https://www.globenewswire.com/NewsRoom/AttachmentNg/5beb073f-f6d4-4e5c-b12c-49d9452e4e8d

GlobeNewswire Distribution ID 8738216

Posted on

Descartes’ Study Reveals 65% of Companies Plan to Accelerate Supply Chain and Logistics Innovation Investment

ATLANTA and LONDON, Jan. 30, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, released findings from its study Supply Chain and Logistics Innovation Accelerates, but Has Long Way to Go, which examined how technology innovation is changing supply chain and logistics operations and executives’ plans for continued investment. The report found that 59% of companies surveyed accelerated the pace of innovation investment and deployment over the last two years. Moreover, 65% plan to increase their technology spending over the next two years; however, 87% indicated they still face internal inhibitors to supply chain and logistics innovation.

The study of 1,000 supply chain and logistics decision-makers across nine European countries, Canada and the United States provides supply chain and logistics organizations with critical insights into the importance of innovation and differences in the strategies, tactics and technology decisions of top financial performers and those companies whose senior management thought innovation was very important.

“The recent past has highlighted that supply chain performance can make or break companies and the need to innovate supply chain and logistics operations has moved to the forefront of many C-suite agendas,” said Chris Jones, EVP, Industry and Services at Descartes. “The study shows that, while efforts in supply chain and logistics innovation are accelerating, many companies are relatively early in their innovation journey in areas such as digitization and especially in the use of advanced computing technologies such as machine learning.”

The study analyzes the connection between innovation and business success, the drivers of supply chain and logistics innovation, the expected benefits of innovation to companies, and the obstacles inhibiting the pace of innovation and innovation investment. The study also examines where supply chain and logistics innovation is considered to be the strongest and the weakest, the degree to which key supply chain and logistics innovative technologies are deployed and innovation focus areas today and in the future. Lastly, it provides insight into how the importance of supply chain and logistics innovation changes on a geodemographic basis. To learn more, read the report Supply Chain and Logistics Innovation Accelerates, but Has Long Way to Go.

About Descartes

Descartes (Nasdaq:DSGX) (TSX:DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, performance and security of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, schedule, track and measure delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com, and connect with us on LinkedIn and Twitter.

Global Media Contact
Cara Strohack                                                    
Tel: +1(800) 419-8495 ext. 202025                        
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes’ most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

GlobeNewswire Distribution ID 8738113

Posted on

JETEX LONDON WELCOMES THE WORLD

Jetex London welcomes the world as the brand’s newest FBO is now fully operational.

Dubai, United Arab Emirates, Jan. 30, 2023 (GLOBE NEWSWIRE) — Located at Hangar 510 at Biggin Hill Airport (EGKB/BQH), Jetex London has commenced full commercial operations and is welcoming international private jet flyers to the United Kingdom capital.

London Biggin Hill is a private airport which caters exclusively for aircraft in business and private aviation. 2022 was the strongest year ever for the airport, with more than 26,000 movements (up from 18,900 in 2021). It is recognized as a global center of excellence and the second private jet operation in the U.K. with 23% of London’s market share after Farnborough (31%) and ahead of Luton (22%). The airport typically connects flights to more than 750 destinations across over 70 countries.

Jetex London is conveniently located just nine miles from Canary Wharf and 15 miles from Central London, with helicopter transfers taking passengers to and from the heart of the British capital in just six minutes, with limousine transfers taking less than 50 minutes.

The modern airport runway (1,806 meters) allows most aircraft to operate without payload or range restrictions, including non-stop transatlantic flights.

“We are pleased with our arrival in London. Jetex already has a strong presence in Europe with a flagship private jet terminal at Paris Le Bourget, and the new flagship Jetex London is a natural evolution of our operations. Private flyers will enjoy a seamless travel experience complemented by the greatest levels of luxury hospitality, while employing the latest technology will allow us to minimize carbon footprint.”

Adel Mardini
Founder & CEO, Jetex

 Jetex London will offer a suite of flagship services for passengers and crews traveling through the airport. It is a seamless, intuitive and dedicated route for Jetex customers to begin or end their journey in supreme comfort. The on-site U.K. Border Force and customs control will ensure that passengers and crew enjoy an efficient ground experience, while Jetex will also offer assistance with ground transport, hotel accommodation, catering, concierge services and much more.

Biggin Hill’s green agenda is key to the airport’s future development, and it echoes the global sustainability commitment of Jetex. The airport has been offering sustainable aviation fuel (SAF) since April 2021.

 “We are extremely proud that Jetex has chosen London Biggin Hill Airport as the destination for its latest FBO – the first in the United Kingdom. Jetex is one of the most respected and acclaimed businesses in private aviation, with an ambitious growth roadmap that reflects our own. We stand at the ready to welcome Jetex’s customers to the capital and offer them the very best standards of service they have come to expect.”

Robert Walters
Commercial Director, London Biggin Hill Airport

With natural materials, soft lighting, and floor-to-ceiling windows, Jetex London is designed to feel like a warm, contemporary space. The 1,900 sq.m. private terminal will include several supremely comfortable lounges of understated luxury designed with passenger privacy in mind, retail and entertainment areas, fully equipped boardrooms, shower suites and much more. Crews will appreciate a full range of on-site recreational and flight support facilities.

Jetex London marks the company’s first entry into the U.K. as it looks forward to growing its operations in the market.

About Jetex:
An award-winning global leader in executive aviation, Jetex is recognized for delivering flexible, best-in-class trip support solutions to customers worldwide. Jetex provides exceptional private terminals (FBOs), aircraft fueling, ground handling and global trip planning. The company caters to both owners and operators of business jets for corporate, commercial and personal air travel. To find out more about Jetex, visit www.jetex.com and follow us on Instagram, Twitter, Facebook, and LinkedIn.

Attachment

Oleg Kafarov - Director of Portfolio Development & Corporate Communications
Jetex
+971 4 212 4900
teamorange@jetex.com

GlobeNewswire Distribution ID 8738614

Proudly powered by WordPress